Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis pill shows promise in early trial

NCT ID NCT05730725

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could significantly reduce psoriasis skin symptoms (measured by PASI-75) and to check for side effects. The study is already completed, and results will help decide if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BMS-986322
What this could lead to
If successful, this could lead to a new oral treatment option for people with moderate-to-severe psoriasis.
What could go wrong
This is an early-phase trial with only 109 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

109 people

The number who actually took part.

Started

Apr 2023

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of plaque psoriasis (PsO) for ≥ 6 months * Body mass index 18 to 40 kg/m\^2 and total body weight \> 50 kg (110 lbs) * Deemed by Investigator to be eligible for phototherapy or systemic therapy * Psoriatic plaques must cover ≥ 10% of body surface area at baseline * Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline Exclusion Criteria: * Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) * Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment * Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Local Institution - 0001

    Los Angeles, California, 90045-3606, United States

  • Local Institution - 0002

    Fremont, California, 94538, United States

  • Local Institution - 0003

    Santa Ana, California, 92701-2201, United States

  • Local Institution - 0004

    Beverly, Massachusetts, 01915-1672, United States

  • Local Institution - 0005

    Fountain Valley, California, 92708-3701, United States

  • Local Institution - 0006

    Birmingham, Alabama, 35205-5021, United States

  • Local Institution - 0007

    Portsmouth, New Hampshire, 03801, United States

  • Local Institution - 0008

    Cleveland, Ohio, 44106-1716, United States

  • Local Institution - 0011

    Webster, Texas, 77598, United States

  • Local Institution - 0012

    Encino, California, 91436, United States

  • Local Institution - 0013

    Coral Gables, Florida, 33134-5736, United States

  • Local Institution - 0016

    Los Angeles, California, 90056, United States

  • Local Institution - 0019

    Carlton, Victoria, 3053, Australia

  • Local Institution - 0020

    Hamilton, Ontario, L8L 3C3, Canada

  • Local Institution - 0023

    tabashi City, Tokyo, 1738606, Japan

  • Local Institution - 0024

    Brisbane, Queensland, 4102, Australia

  • Local Institution - 0026

    Nagoya, 467-8602, Japan

  • Local Institution - 0027

    Tsu, 514-8507, Japan

  • Local Institution - 0030

    Toronto, Ontario, M2N 3A6, Canada

  • Local Institution - 0034

    Barrie, Ontario, L4M 7G1, Canada

  • Local Institution - 0041

    London, Ontario, N6A 2C2, Canada

  • Local Institution - 0042

    Itabashi-Ku, 173-8610, Japan

  • Local Institution - 0044

    Clarksville, Indiana, 47129-2201, United States

  • Local Institution - 0045

    Pascoe Vale South, Victoria, 3044, Australia

  • Local Institution - 0046

    Leytonstone, E11 1NR, United Kingdom

  • Local Institution - 0049

    Sapporo, Hokkaido, 064-0807, Japan

  • Local Institution - 0050

    Hinckley, LEC, LE10 2SE, United Kingdom

  • Local Institution - 0051

    Fukuoka, 814-0180, Japan

  • Local Institution - 0055

    Durham, North Carolina, 27713-8507, United States

  • Local Institution - 0056

    Skokie, Illinois, 60077-1049, United States

  • Local Institution - 0057

    Leawood, Kansas, 66211, United States

  • Local Institution - 0058

    Rapid City, South Dakota, 57702-9208, United States

  • Local Institution - 0059

    Dallas, Texas, 75230-5808, United States

  • Local Institution - 0060

    Lee's Summit, Missouri, 64064, United States

  • Local Institution - 0062

    St. John's, Newfoundland and Labrador, A1E 1V4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.